consistent with the adult indications of the originator biologic Stelara ® ** Logo de Fresenius Kabi (CNW Group/Fresenius Kabi Canada Inc.) "The launch of Otulfi™ is an important milestone on ...

TORONTO, May 27, 2025 /CNW/ - Fresenius Kabi Canada announces that its ustekinumab biosimilar, developed by Formycon AG, is now commercially available in Canada. Otulfi ™ is indicated for the ...

With this launch, Fresenius Kabi Canada's immunology biosimilar portfolio is further expanding, offering more treatment options for patients with chronic autoimmune conditions Tyenne ® is Fresenius ...

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its commercialization partner Fresenius Kabi announce that the UK Medicines and Healthcare products Regulatory ...

moderate to severe plaque psoriasis and active psoriatic arthritis indications of its originator biologic Stelara ®** Fresenius Kabi logo (CNW Group/Fresenius Kabi Canada Inc.) "This is Fresenius ...

Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announces they have signed a development agreement that leverages each company’s expertise in cell and gene therapies (CGTs).

Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies ...

In February 2023, Formycon and Fresenius Kabi entered into a global license agreement providing Fresenius Kabi with commercialization rights for FYB202 in key global markets. Semi-exclusive ...

Fresenius Kabi Philippines, Inc.—a global healthcare company that focuses on lifesaving medicines for infusion, transfusion, and clinical nutrition welcomed the first quarter of the year with ...

Fresenius Kabi began the recall at the end of November. It covers only LVP-0004 models of the large-volume pump that were distributed between October 2021 and July of last year—938 of which were ...